503 related articles for article (PubMed ID: 22305462)
1. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
[TBL] [Abstract][Full Text] [Related]
2. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC;
Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202
[TBL] [Abstract][Full Text] [Related]
3. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
[TBL] [Abstract][Full Text] [Related]
4. Apixaban in patients with atrial fibrillation.
Connolly SJ; Eikelboom J; Joyner C; Diener HC; Hart R; Golitsyn S; Flaker G; Avezum A; Hohnloser SH; Diaz R; Talajic M; Zhu J; Pais P; Budaj A; Parkhomenko A; Jansky P; Commerford P; Tan RS; Sim KH; Lewis BS; Van Mieghem W; Lip GY; Kim JH; Lanas-Zanetti F; Gonzalez-Hermosillo A; Dans AL; Munawar M; O'Donnell M; Lawrence J; Lewis G; Afzal R; Yusuf S;
N Engl J Med; 2011 Mar; 364(9):806-17. PubMed ID: 21309657
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
[TBL] [Abstract][Full Text] [Related]
6. The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial.
Hohnloser SH; Shestakovska O; Eikelboom J; Franzosi MG; Tan RS; Zhu J; Yusuf S; Connolly SJ
Eur Heart J; 2013 Sep; 34(35):2752-9. PubMed ID: 23892201
[TBL] [Abstract][Full Text] [Related]
7. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
[TBL] [Abstract][Full Text] [Related]
8. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
9. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
10. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
15. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Eikelboom J; Yusuf S; Shestakovska O; Hart RG; Connolly S;
Stroke; 2014 Jul; 45(7):2127-30. PubMed ID: 24916911
[TBL] [Abstract][Full Text] [Related]
16. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W;
Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
20. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
